GLAUKOS CORPORATION (NYSE:GKOS) Files An 8-K Regulation FD Disclosure

Item 7.01

Glaukos Corporation (the Company) intends to present the
materials attached as Exhibit99.1 to this Current Report on
Form8-K (the Investor Presentation) from time to time in
presentations to investors and other stakeholders. The Investor
Presentation will also be available on the investor pageof the
Companys website at http://investors.glaukos.com.

The information in this Item 7.01 (including Exhibit99.1) shall
not be deemed filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities of that section, and is not incorporated by reference
into any filing of the Company whether made before or after the
date hereof, regardless of any general incorporation language in
such filing.

(d) Exhibits

About GLAUKOS CORPORATION (NYSE:GKOS)

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye’s anterior chamber through a corneal incision. The Company’s micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

GLAUKOS CORPORATION (NYSE:GKOS) Recent Trading Information

GLAUKOS CORPORATION (NYSE:GKOS) closed its last trading session up +0.48 at 46.02 with 717,641 shares trading hands.